The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology

Acta Cytologica

Volumn 56, Issue 5, 2012, Pages 527-532

  Hyun, Teresa S ^a   Barnes, Michael ^a   Laura Tabatabai, Z ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Calretinin; CK5 6; D2 40; Desmin; Immunohistochemistry; Mesothelioma; MOC 31; Pleural effusion cytology

Indexed keywords

CALRETININ; CYTOKERATIN 5; CYTOKERATIN 6; DESMIN; MONOCLONAL ANTIBODY D2-40;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL POPULATION; CLINICAL ARTICLE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MESOTHELIUM; PLEURA EFFUSION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 84867699402     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000339586     Document Type: Article

References (31)

1. Chu AY, Litzky LA, Pasha TL, et al: Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005; 18: 105-110.
2. Ordóñez NG: D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005; 36: 372-380.
3. Müller AM, Franke FE, Müller KM: D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Pathobiology 2006; 73: 50-54.
4. Marks A, Sutherland DR, Bailey D, et al: Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999; 80: 569-578.
5. Breiteneder-Geleff S, Matsui K, Soleiman A, et al: Podoplanin, a novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997; 151: 1141-1152.
6. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplain as a specific marker for lymphatic endothelium. Am J Pathol 1999; 154: 385-394.
7. Weninger W, Partanen TA, Breiteneder-Geleff S, et al: Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999; 79: 243-251.
8. Kahn HJ, Bailey D, Marks A: Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002; 15: 434-440.
9. Kalof AN, Cooper K: D2-40 immunohistochemistry-so far! Adv Anat Pathol 2009; 16: 62-64.
10. Shield PW, Koivurinne K: The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Cytopathology 2008; 19: 218-223.
11. Ruitenbeek T, Gouw AS, Poppema S: Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 1994; 118: 265-269.
12. Morgan RL, De Young BR, McGaughy VR, et al: MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer 1999; 87: 390-394.
13. Oates J, Edwards C: HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000; 36: 341-347.
14. Gill SA, Meier PA, Kendall BS: Use of desmin immunohistochemistry to distinguish between mesothelial cells and carcinoma in serous fluid cell block preparations. Acta Cytol 2000; 44: 976-980.
15. Davidson B, Nielsen S, Christensen J, et al: The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001; 25: 1405-1412.
16. Ferrandez-Izquierdo A, Navarro-Fos S, Gonzalez-Devesa M, et al: Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models. Diagn Cytopathol 1994; 10: 256-262.
17. Mimura T, Ito A, Sakuma T, et al: Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer 2007; 109: 933-938.
18. Kao SC, Griggs K, Lee K, et al: Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology 2011; 43: 313-317.
19. Hinterberger M, Reineke T, Storz M, et al: D2-40 and calretinin-a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol 2007; 20: 248-255.
20. Saleh HA, El-Fakharany M, Makki H, et al: Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunochtochemical panel in the differential diagnosis. Diagn Cytopathol 2009; 37: 324-332.
21. Kim JH, Kim GE, Choi YD, et al: Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks. Diagn Cytopathol 2009; 37: 258-261.
22. Bassarova AV, Nesland JM, Davidson B: D2-is not a specific marker for cells of mesotheilal origin in serous effusions. Am J Surg Pathol 2006; 30: 878-882.
23. Ordóñez NG: The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006; 19: 34-48.
24. Hanna A, Pang Y, Bedrossian CW, et al: Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol 2010; 38: 264-269.
25. Ordóñez NG: Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol 2006; 13: 16-25.
26. Lee BH, Hecht JL, Pinkus JL, et al: WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 2002; 117: 745-750.
27. Hasteh F, Lin GY, Weidner N, et al: The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol 2010; 118: 90-96.
28. Attanoos RL, Griffin A, Gibbs AR: The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, Pglycoprotein and Bcl-2. Histopathology 2003; 43: 231-238.
29. Afify AM, Al-Khafaji BM, Paulino AFG, et al: Diagnostic use of muscle markers in the cytologic evaluation of serous fluids. Appl Immunohistochem Mol Morphol 2002; 10: 178-182.
30. Hecht JL, Pinkus JL, Pinkus GS: Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations. Cancer Cytopathol 2006; 108: 56-59.
31. Kundu UR, Krishnamurthy S: Use of the monoclonal antibody MOC-31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology. Cancer Cytopathol 2011; 119: 272-278.